Ephrin receptor 3D structures: Difference between revisions
Jump to navigation
Jump to search
Michal Harel (talk | contribs) New page: == 3D Structures of ephrin receptors == Updated on {{REVISIONDAY2}}-{{MONTHNAME|{{REVISIONMONTH}}}}-{{REVISIONYEAR}} {{#tree:id=OrganizedByTopic|openlevels=0| *Ephrin A1 receptor **[[3k... |
Michal Harel (talk | contribs) No edit summary |
||
(2 intermediate revisions by the same user not shown) | |||
Line 11: | Line 11: | ||
**[[1x5a]] - hEPHR A1 fn3 domain – NMR<BR | **[[1x5a]] - hEPHR A1 fn3 domain – NMR<BR | ||
*Ephrin A2 receptor; domains – LBD 28-200; ectodomain 27-435; kinase 596-900 | *Ephrin A2 receptor; domains – LBD 28-200; ectodomain 27-435; kinase 596-900; SAM fragment 945-969 | ||
**[[3hpn]], [[3c8x]] - hEPHR A2 LBD<BR /> | **[[3hpn]], [[3c8x]] - hEPHR A2 LBD<BR /> | ||
Line 17: | Line 17: | ||
**[[2k9y]], [[2e8n]] - hEPHR A2 transmembrane domain – NMR<BR /> | **[[2k9y]], [[2e8n]] - hEPHR A2 transmembrane domain – NMR<BR /> | ||
**[[1mqb]], [[4p2k]], [[4pdo]], [[4trl]], [[5ek7]], [[5i9u]] - hEPHR A2 kinase domain<BR /> | **[[1mqb]], [[4p2k]], [[4pdo]], [[4trl]], [[5ek7]], [[5i9u]] - hEPHR A2 kinase domain<BR /> | ||
**[[7kja]] - hEPHR A2 kinase+SAM domains<br /> | |||
**[[7kjb]], [[7kjc]] - hEPHR A2 kinase+SAM domains (mutant)<br /> | |||
*''Ephrin A2 receptor binary complex''<br /> | *''Ephrin A2 receptor binary complex''<br /> | ||
Line 24: | Line 26: | ||
**[[3mbw]] - hEPHR A2 LBD + carbohydrate-recognition domain + ephrin A1<br /> | **[[3mbw]] - hEPHR A2 LBD + carbohydrate-recognition domain + ephrin A1<br /> | ||
**[[6njz]], [[6nk0]], [[6nk1]], [[6nk2]], [[6nkp]], [[6b9l]] - hEPHR A2 LBD + peptide<br /> | **[[6njz]], [[6nk0]], [[6nk1]], [[6nk2]], [[6nkp]], [[6b9l]] - hEPHR A2 LBD + peptide<br /> | ||
**[[6rw2]] - hEPHR A2 LBD + bicycle toxin<br /> | |||
**[[7b7n]], [[7cze]], [[7czf]] - hEPHR A2 LBD + herpesvirus glycoproteins<br /> | |||
**[[2kso]] - hEPHR A2 SAM fragment residues 945-969 + SHIP2<br /> | **[[2kso]] - hEPHR A2 SAM fragment residues 945-969 + SHIP2<br /> | ||
**[[5nz9]] - hEPHR A2 SAM fragment<br /> | **[[5nz9]] - hEPHR A2 SAM fragment - NMR<br /> | ||
**[[5i9v]], [[5i9w]], [[5njz]], [[5nk0]], [[5nk1]], [[5nk2]], [[5nk3]], [[5nk4]], [[5nk5]], [[5nk6]], [[5nk7]], [[5nk8]], [[5nk9]], [[5nka]], [[5nkb]], [[5nkc]], [[5nkd]], [[5nke]], [[5nkf]], [[5nkg]], [[5nkh]], [[5nki]] - hEPHR A2 kinase domain + inhibitor<br /> | **[[6f7m]], [[6f7n]] - hEPHR A2 SAM fragment (mutant) - NMR<br /> | ||
**[[5i9v]], [[5i9w]], [[5njz]], [[5nk0]], [[5nk1]], [[5nk2]], [[5nk3]], [[5nk4]], [[5nk5]], [[5nk6]], [[5nk7]], [[5nk8]], [[5nk9]], [[5nka]], [[5nkb]], [[5nkc]], [[5nkd]], [[5nke]], [[5nkf]], [[5nkg]], [[5nkh]], [[5nki]], [[6hes]], [[6het]], [[6heu]], [[6hev]], [[6hew]], [[6hex]], [[6hey]], [[6q7b]], [[6q7c]], [[6q7d]], [[6q7e]], [[6q7f]], [[6q7g]], [[8bin]], [[8bio]], [[8bk0]] - hEPHR A2 kinase domain + inhibitor<br /> | |||
**[[6fnf]], [[6fng]], [[6fnh]] – hEPHR A2 kinase domain + pyrimidine derivative<br /> | **[[6fnf]], [[6fng]], [[6fnh]] – hEPHR A2 kinase domain + pyrimidine derivative<br /> | ||
**[[5i9x]], [[5i9y]], [[5i9z]], [[5ia0]], [[5ia1]], [[5ia2]], [[5ia3]], [[5ia4]], [[5ia5]] - hEPHR A2 kinase domain + kinase drug<br /> | **[[5i9x]], [[5i9y]], [[5i9z]], [[5ia0]], [[5ia1]], [[5ia2]], [[5ia3]], [[5ia4]], [[5ia5]] - hEPHR A2 kinase domain + kinase drug<br /> | ||
Line 36: | Line 41: | ||
**[[3fxx]], [[3fy2]] – hEPHR A3 kinase domain + peptide substrate<BR /> | **[[3fxx]], [[3fy2]] – hEPHR A3 kinase domain + peptide substrate<BR /> | ||
**[[2qoq]], [[2qo7]], [[2qo9]], [[2qoc]] - hEPHR A3 kinase domain + AMP-PNP<BR /> | **[[2qoq]], [[2qo7]], [[2qo9]], [[2qoc]] - hEPHR A3 kinase domain + AMP-PNP<BR /> | ||
**[[3dzq]], [[4gk2]], [[4gk3]], [[4gk4]], [[4p5q]], [[4p5z]], [[4p4c]], [[4twn]], [[4two]] - hEPHR A3 kinase domain + inhibitor<br /> | **[[3dzq]], [[4gk2]], [[4gk3]], [[4gk4]], [[4p5q]], [[4p5z]], [[4p4c]], [[4twn]], [[4two]], [[6in0]] - hEPHR A3 kinase domain + inhibitor<br /> | ||
**[[4g2f]] - hEPHR A3 kinase domain (mutant) + inhibitor<br /> | **[[4g2f]] - hEPHR A3 kinase domain (mutant) + inhibitor<br /> | ||
**[[4l0p]] - hEPHR A3 LBD + Ephrin-A5<br /> | **[[4l0p]] - hEPHR A3 LBD + Ephrin-A5<br /> | ||
Line 45: | Line 50: | ||
**[[4bk4]], [[4m4p]] - hEPHR A4 ectodomain<br /> | **[[4bk4]], [[4m4p]] - hEPHR A4 ectodomain<br /> | ||
**[[2lw8]] - hEPHR A4 LBD – NMR<br /> | **[[2lw8]] - hEPHR A4 LBD – NMR<br /> | ||
**[[7ofv]] - hEPHR A4 LBD + polypeptide inhibitor<br /> | |||
**[[6fnl]] – hEPHR A4 kinase domain<br /> | **[[6fnl]] – hEPHR A4 kinase domain<br /> | ||
**[[2hel]] – mEPHR A4 membrane and kinase domains – mouse<br /> | **[[2hel]] – mEPHR A4 membrane and kinase domains – mouse<br /> | ||
Line 73: | Line 79: | ||
**[[3h8m]] – hEPHR A7 SAM<BR /> | **[[3h8m]] – hEPHR A7 SAM<BR /> | ||
**[[2rei]] - hEPHR A7 kinase domain<BR /> | **[[2rei]] - hEPHR A7 kinase domain<BR /> | ||
**[[7eec]], [[7eed]], [[7eef]] - hEPHR A7 kinase domain (mutant) <br /> | |||
**[[3dko]] – hEPHR A7 kinase domain + inhibitor | **[[3dko]] – hEPHR A7 kinase domain + inhibitor | ||
Line 88: | Line 95: | ||
**[[5mja]] - hEPHR B1 kinase domain + inhibitor<br /> | **[[5mja]] - hEPHR B1 kinase domain + inhibitor<br /> | ||
**[[5mjb]] - hEPHR B1 kinase domain (mutant) + inhibitor<br /> | **[[5mjb]] - hEPHR B1 kinase domain (mutant) + inhibitor<br /> | ||
**[[6umw]] - hEPHR B1 kinase domain + antibiotics<br /> | |||
**[[7kpl]] - hEPHR B1 172-450 <br /> | |||
**[[7kpm]] - hEPHR B1 172-450 + ADP<br /> | |||
*Ephrin B2 receptor | *Ephrin B2 receptor | ||
Line 125: | Line 135: | ||
**[[2xvd]], [[2yn8]], [[4bb4]] - hEPHR B4 kinase domain (mutant) + inhibitor<br /> | **[[2xvd]], [[2yn8]], [[4bb4]] - hEPHR B4 kinase domain (mutant) + inhibitor<br /> | ||
**[[2hle]], [[2bba]] - hEPHR B4 LBD + ephrin B2 | **[[2hle]], [[2bba]] - hEPHR B4 LBD + ephrin B2 | ||
*Ephrin B6 receptor | |||
**[[7k7j]] - hEPHR B6 ectodomain<br /> | |||
}} | }} | ||
[[Category:Topic Page]] | [[Category:Topic Page]] |
Latest revision as of 14:31, 21 February 2023
3D Structures of ephrin receptors3D Structures of ephrin receptors
Updated on 21-February-2023